壳聚糖携载质粒纳米微球体外转染兔关节软骨细胞的实验研究

目的:研究携载质粒的不同分子量的壳聚糖纳米微球的包裹率和保护DNA的能力,镜下观察其大小和形态,观察其对原代兔关节软骨细胞的转染效率。方法:利用酶消化法消化3周龄新西兰大白兔的关节软骨,贴壁培养原代兔关节软骨细胞。购买相对分子量在5K和800K之间的八种壳聚糖,利用表达增强型绿色荧光蛋白的质粒(pEGFP)作报告基因,通过复合凝聚法制备壳聚糖-质粒纳米微球。琼脂糖凝胶电泳、紫外分光光度计分析不同N/P比值对不同分子量壳聚糖和质粒的结合能力及包封率的影响;纳米粒度仪、透射电子显微镜和环境扫描电子显微镜考察纳米微球的粒径分布和形态;荧光显微镜观察壳聚糖纳米微球介导pEGFP在体外培养的兔关节软骨细胞中的表达情况;流失细胞仪计算具体转染效率。结果:①N/P值为4及4以上时,各分子量的壳聚糖可完全包裹质粒成球;N/P值为2时,分子量为5K、50K、85K仅部分包裹质粒,其余可完全包裹;N/P值为1时,各壳聚糖均与质粒部分包裹;N/P值为0.25时,各壳聚糖均与质粒完全分离。②纳米粒度仪分析得出:N/P值为4时,各分子量的壳聚糖纳米微球的平均粒径均在1微米以下,③透射电子显微镜和扫描电子显微镜均可观察到球形或不规则形的大小不同的微球。荧光显微镜可大致观察到绿色荧光蛋白在软骨细胞内表达的表达情况。④流式细胞仪得出具体转染效率,分子量为170K、250K和800K的壳聚糖纳米微球的转染效率均高于5K、50K和85K的壳聚糖纳米微球,其中800K的壳聚糖纳米微球与脂质体相当(差异有统计学意义,P<0.05)。结论:与脂质体相比,N/P比值为4时,相对分子量为800k的壳聚糖纳米微球可高效转染原代培养的兔软骨细胞,可以作为今后进一步体外、体内实验的首选转染载体。     

壳聚糖携载质粒纳米微球体外转染兔关节软骨细胞的实验研究

目的：研究携载质粒的不同分子量的壳聚糖纳米微球的包裹率和保护DNA的能力,镜下观察其大小和形态,观察其对原代兔关节软骨细胞的转染效率。方法：利用酶消化法消化3周龄新西兰大白兔的关节软骨,贴壁培养原代兔关节软骨细胞。购买相对分子量在5K和800K之间的八种壳聚糖,利用表达增强型绿色荧光蛋白的质粒（pEGFP）作报告基因,通过复合凝聚法制备壳聚糖-质粒纳米微球。琼脂糖凝胶电泳、紫外分光光度计分析不同N/P比值对不同分子量壳聚糖和质粒的结合能力及包封率的影响;纳米粒度仪、透射电子显微镜和环境扫描电子显微镜考察纳米微球的粒径分布和形态;荧光显微镜观察壳聚糖纳米微球介导pEGFP在体外培养的兔关节软骨细胞中的表达情况;流失细胞仪计算具体转染效率。结果：①N/P值为4及4以上时,各分子量的壳聚糖可完全包裹质粒成球;N/P值为2时,分子量为5K、50K、85K仅部分包裹质粒,其余可完全包裹;N/P值为1时,各壳聚糖均与质粒部分包裹;N/P值为0.25时,各壳聚糖均与质粒完全分离。②纳米粒度仪分析得出：N/P值为4时,各分子量的壳聚糖纳米微球的平均粒径均在1微米以下,③透射电子显微镜和扫描电子显微镜均可观察到球形或不规则形的大小不同的微球。荧光显微镜可大致观察到绿色荧光蛋白在软骨细胞内表达的表达情况。④流式细胞仪得出具体转染效率,分子量为170K、250K和800K的壳聚糖纳米微球的转染效率均高于5K、50K和85K的壳聚糖纳米微球,其中800K的壳聚糖纳米微球与脂质体相当（差异有统计学意义,P〈0.05）。结论：与脂质体相比,N/P比值为4时,相对分子量为800k的壳聚糖纳米微球可高效转染原代培养的兔软骨细胞,可以作为今后进一步体外、体内实验的首选转染载体。     

姜黄素壳聚糖微球的制备及其在体内外释放度的研究

目的:研究响应面法优化姜黄素壳聚糖微球制备的工艺参数,提高姜黄素的溶出度.方法:采用离子交联法制备姜黄素缓释微球,以微球的载药量和包封率为考察指标,采用星点设计考察配制壳聚糖的醋酸浓度、药物载体的比例以及交联剂浓度对微球制备工艺的影响,对结果进行二次多项式拟合,并根据最佳数学模型进行预测.结果:姜黄素壳聚糖微球最优制备工艺参数为:醋酸的浓度为1％,载体药物比例为0.83,交联剂的浓度为0.15％,载药量和包封率的预测值和理论值偏差分别为0.47％和3.2％.结论:响应面法优化姜黄素壳聚糖微球制剂处方具有很好的预测性,体内外药物释放度研究表明,最优条件下制备的微球可以在提高姜黄素溶出度的前提下缓慢释放达12h.     

重组人粒细胞集落刺激因子缓释微球的研究

目的：研究固体／油／水法制备重组人粒细胞集落刺激因子缓释微球,为开发其缓释剂型进行初步研究。方法：以聚乳酸．聚羟乙酸共聚物（PLGA）为载体材料：用固体／油／水法和水／油／水法制备载rhG-CSF缓释微球;考察粒径大小、外观、包封率等理化性质;用MieroBCA法考察微球的体外释药特性及影响因素;用SEC-HPLC和MTT比色法初步评价了微球制备工艺过程对rhG-CSF稳定性的影响。结果：两种方法制得的微球形态圆整、分散性良好,包封率均超过80％。固／油／水法制得的微球体外释放在2周内可超过90％,而水／油／水法制得的微球在相同的时间内仅释放30％。对于固／油／水法制备过程,SEC-HPLC法测定蛋白无明显聚集体出现,MTT法测定蛋白活性无明显损失。结论：实验证明了固／油／水法制备的PLGA微球可以实现2周以上的体外缓释。     

可控性释放NGF的京尼平- 壳聚糖微球的研究

目的:在体外研究京尼平-壳聚糖微球可控性释放具有生物活性的神经生长因子的可行性。方法:采用"乳化-化学交联"技术制备包埋神经生长因子的京尼平-壳聚糖微球,京尼平为化学交联剂;应用扫描电镜、粒径分布、体外缓释动力学及细胞生物活性分别对微球的性能进行研究。结果:京尼平-壳聚糖微球表面光滑,平均粒径在5.1~50.5μm之间;京尼平的浓度可影响微球在体外释放神经生长因子的速度,经高浓度京尼平交联的微球能减缓并持续释放神经生长因子;此外,从京尼平-壳聚糖微球释放的神经生长因子可维持PC12细胞的生物活性,提高NGF生物利用率。结论:京尼平-壳聚糖微球能有效缓释具有生物活性的NGF超过14天,为神经退行性疾病的治疗提供一种治疗策略。     

改善蛋白质药物PELA控释微球释放性能的研究

开展了以乙酸乙酯(EA)与二氯甲烷(MC)的混合溶液为有机溶剂、以单甲氧基聚乙二醇-聚-DL-乳酸(PELA)为膜材的W／O／W复乳-分步固化法制备蛋白质药物控释微球的研究。为解决微球突释率高、且突释后的释药速度缓慢的问题,实现后期快速释放,以溶菌酶为模型蛋白,重点考察了膜材组成、内水相体积以及外水相盐浓度对微球释药速率的影响。结果表明,当外水相盐浓度增大至1.5％时可将释放率由22％提升至45％,是一种较好的加快微球释药速率的途径,因此可通过选择适当的外水相盐浓度,达到所期望的药物释药速率。     

多西紫杉醇白蛋白微球的制备及优化实验研究

多西紫杉醇(DT)是唯一应用于临床治疗肿瘤的紫杉醇的衍生物,其水溶性差,制剂中需要加入有机溶剂和助溶剂,而有机溶剂和助溶剂具有刺激性。为减少多西紫杉醇制剂的刺激性,本实验通过去溶剂化—化学交联法制备水溶性多西紫杉醇白蛋白微球。对制备过程中的重要影响因素进行考察,并通过Design-expert软件进行数据优化,最终得优化条件:白蛋白浓度为35 mg.mL-1,DT浓度为1.03 mg.mL-1,乙醇和水的比例为3∶1,乙醇的滴加速度为0.73 mL.min-1,搅拌时间为12 h,0.2%戊二醛与白蛋白的交联比为2∶1。得到的多西紫杉醇白蛋白微球粒径为185 nm,载药量为14.4%,成功的解决了其水溶性,为接下来的动物实验、临床应用提供了良好的基础。     

苄丝肼微球的体外释放行为

采用S/O/W和W/O/W法,和不同的苄丝肼载药量制作缓释微球,用HPLC考察其释放曲线、突释情况和包封率,实验表明S/O/W法制作的苄丝肼微球缓释效果更好,达到了6d,包封率能达到70%以上,突释情况可以接受,苄丝肼载药量低的微球能达到更高的包封率。     

担载b-FGF的PLGA微球复合明胶支架的体外释放研究

目的:研究担载碱性成纤维细胞生长因子(b-FGF)微球复合明胶支架的外形特征、孔径、孔隙率及体外释放动力学,以期构建具有缓释功能、高孔隙率的担载细胞因子的新型复合明胶支架。方法:本文利用冷冻相分离法和S/O/W法先将b-FGF水溶液包裹于PLGA微球中,然后埋置于明胶溶液中制备为多孔复合明胶支架。分别对微球的形态和复合明胶支架的基本形态、孔径、孔隙率进行表征,通过Elisa法测定b-FGF在复合明胶支架中的体外释放行为。结果:制备成形态良好的三维复合明胶支架,其孔隙率为82.90%±1.45%,孔径范围为150~300μm,复合明胶支架中b-FGF在体外缓慢释放20余天。结论:担载蛋白微球复合明胶支架不仅满足组织工程支架的要求,还能有效缓释细胞因子,为细胞和组织生长提供良好的微环境,为进一步应用于组织工程领域提供了可能。     

牛血清白蛋白在聚乙二醇/葡聚糖双水相体系中分配特性的研究

采用考马斯亮蓝G250染色法测得室温下BSA在PEG/dextran双水相体系中的分配系数。以BSA在PEG/dextran体系的下相富集为目标,研究了PEG的分子量、浓度、dextran浓度以及所加入中性盐的种类与浓度、体系pH诸因素对其分配特性的影响。实验结果表明,在PEG4000/dextran体系中,采用PEG质量分数9%-dextran质量分数9%的浓度组成,同时在pH=7.0,NaC l浓度为0.2 mol.L-1或pH6.0,NaC l浓度为0.34 mol.L-1的工艺条件下萃取BSA均可达最小分配系数,其值为0.014。     

一种白细胞介素-2缓释微球制备新方法及体外表征

目的：开发一种白细胞介素-2（m-2）长效缓释微球剂型。方法：采用S／O／W法制备了白介素-2因子多糖微粒的PLGA微球,考察了微球的表面形态、粒径分布等,并且运用ELISA方法考察了微球的体外释放效果。结果：本方法制备的白介素-2因子微球光滑圆整,粒径分布较均匀,体外缓释达32天,累积释放率近90％。结论：本方法制备的白介素-2因子微球,不仅具有有效地保护IL-2蛋白活性,同时实现长效缓释的目标,是一种可行的蛋白缓释方案。     

Quantifying division of aortal smooth muscle cells in culture stimulated by 1,25(OH)2D3

Inhibitory effect of 1,25dihydroxycholecalciferol (1,25D₃ = calcitriol) in different cell type is well recognized but its promoting effect on vascular smooth muscle cells (SMCs) is poor established. Therefore, the aim of this study was to determine stimulatory effect of calcitriol on aortal SMCs proliferation in culture. We used the cell division analysis procedure based on the quantitative sequential halving of the stably incorporating fluorescent dye carboxyfluorescein diacetate succinimidyl ester (CFSE). This technique allowed the visualization of cycles of SMCs division by flow cytometry. Rat aortal SMCs were labeled with CFSE and cultured for up to 10 days with defined concentration of calcitriol in medium. Proliferative activity as the percentage of SMCs in different phases of the cell cycle using propidium iodide was determined. Apoptosis was assessed using Annexin-V/CFDA method. The results suggest that low concentrations of an active form of vitamin D—1,25dihydroxycholecalciferol applied in supraphysiological concentration of 10 nmol/l is a mitogenic factor for aortal SMCs. None of the applied concentrations of calcitriol caused apoptosis. The findings well support our morphological (LM) and ultrastructural (TEM and SEM) observations.     

Phosphate uptake in chick kidney cells: effects of 1,25(OH)2D3 and 24,25(OH)2D3

Phosphate homeostasis is controlled in part by absorption from the intestine, and reabsorption in the kidney. While the effect of Vitamin D metabolites on enterocytes is well documented, in the current study we assess selected responses in primary cultures of kidney cells. Time course studies revealed a rapid stimulation of phosphate uptake in cells treated with 1,25(OH)(2)D(3), relative to controls. Dose-response studies indicated a biphasic curve with optimal stimulation at 300 pM 1,25(OH)(2)D(3) and inhibition at 600 pM seco-steroid. Antibody 099--against the 1,25D(3)-MARRS receptor - abolished stimulation by the steroid hormone. Moreover, phosphate uptake was mediated by the protein kinase C pathway. The metabolite 24,25(OH)(2)D(3), which was found to inhibit the rapid stimulation of phosphate uptake in intestinal cells, had a parallel effect in cultured kidney cells. Finally, the 24,25(OH)(2)D(3) binding protein, catalase, was assessed for longer term down regulation. In both intestinal epithelial cells and kidney cells incubated with 24,25(OH)(2)D(3) for 5-24h, both the specific activity of the enzyme and protein levels were decreased relative to controls, while 1,25(OH)(2)D(3) increased both parameters over the same time periods. We conclude that the Vitamin D metabolites have similar effects in both kidney and intestine, and that 24,25(OH)(2)D(3) may have effects at the level of gene expression.     

Caffeine decreases vitamin D receptor protein expression and 1,25(OH)2D3 stimulated alkaline phosphatase activity in human osteoblast cells

Of the various risk factors contributing to osteoporosis, dietary/lifestyle factors are important. In a clinical study we reported that women with caffeine intakes >300 mg/day had higher bone loss and women with vitamin D receptor (VDR) variant, tt were at a greater risk for this deleterious effect of caffeine. However, the mechanism of how caffeine effects bone metabolism is not clear. 1,25-Dihydroxy vitamin D₃ (1,25(OH)₂D₃) plays a critical role in regulating bone metabolism. The receptor for 1,25(OH)₂D₃, VDR has been demonstrated in osteoblast cells and it belongs to the superfamily of nuclear hormone receptors. To understand the molecular mechanism of the role of caffeine in relation to bone, we tested the effect of caffeine on VDR expression and 1,25(OH)₂D₃ mediated actions in bone. We therefore examined the effect of different doses of caffeine (0.2, 0.5, 1.0 and 10 mM) on 1,25(OH)₂D₃ induced VDR protein expression in human osteoblast cells. We also tested the effect of different doses of caffeine on 1,25(OH)₂D₃ induced alkaline phosphatase (ALP) activity, a widely used marker of osteoblastic activity. Caffeine dose dependently decreased the 1,25(OH)₂D₃ induced VDR expression and at concentrations of 1 and 10 mM, VDR expression was decreased by about 50–70%, respectively. In addition, the 1,25(OH)₂D₃ induced alkaline phosphatase activity was also reduced at similar doses thus affecting the osteoblastic function. The basal ALP activity was not affected with increasing doses of caffeine. Overall, our results suggest that caffeine affects 1,25(OH)₂D₃ stimulated VDR protein expression and 1,25(OH)₂D₃ mediated actions in human osteoblast cells.     

Microfabricated Pseudocapacitors Using Ni(OH)2 Electrodes Exhibit Remarkable Volumetric Capacitance and Energy Density

Metal hydroxide based microfabricated pseudocapacitors with impressive volumetric stack capacitance and energy density are demonstrated. A combination of top‐down photolithographic process and bottom‐up chemical synthesis is employed to fabricate the micro‐pseudocapacitors (μ‐pseudocapacitors). The resulting Ni(OH)₂‐based devices show several excellent characteristics including high‐rate redox activity up to 500 V s^–1 and an areal cell capacitance of 16 mF cm^–2 corresponding to a volumetric stack capacitance of 325 F cm^–3. This volumetric capacitance is two‐fold higher than carbon and metal oxide based μ‐supercapacitors with interdigitated electrode architecture. Furthermore, these μ‐pseudocapacitors show a maximum energy density of 21 mWh cm^–3, which is superior to the Li‐based thin film batteries. The heterogeneous growth of Ni(OH)₂ over the Ni surface during the chemical bath deposition is found to be the key parameter in the formation of uniform monolithic Ni(OH)₂ mesoporous nanosheets with vertical orientation, responsible for the remarkable properties of the fabricated devices. Additionally, functional tandem configurations of the μ‐pseudocapacitors are shown to be capable of powering a light‐emitting diode.     

Clusterin over-expression modulates proapoptotic and antiproliferative effects of 1,25(OH)2D3 in prostate cancer cells in vitro

Prostate cancer is the most commonly diagnosed cancer in the majority of western countries. Due to their antiproliferative and proapoptotic activity, vitamin D analogues have been introduced recently as an experimental therapy for prostate cancer. Clusterin (CLU) is a glycoprotein that has two known isoforms generated in human cells. A nuclear form of CLU protein (nCLU) is pro-apoptotic, and a secretory form (sCLU) is pro-survival. In this study, we analyzed whether proapoptotic and antiproliferative effects of 1,25(OH)₂D₃ on LNCaP prostate cancer cells are modulated by expression of sCLU. Using colony forming assay, we studied the effect of treatment with different doses of 1,25(OH)₂D₃ (10⁻⁶, 10⁻⁷, 10⁻¹⁰ M) on proliferation of LNCaP cells that were stable transfected and over-express sCLU (LNT-1) as compared to empty vector-transfected cells (LN/C). We also measured apoptosis using TUNEL assay. sCLU over-expression protected against both antiproliferative (30%) and proapoptotic (15%) effects of 1,25(OH)₂D₃, although this effect was statistically not significant. In conclusion, our findings demonstrate that expression of sCLU modulates growth regulatory effects of 1,25(OH)₂D₃ in prostate cancer indicating that CLU interferes with vitamin D signalling pathways.     

Inverted Design for High‐Performance Supercapacitor Via Co(OH)2‐Derived Highly Oriented MOF Electrodes

Metal organic frameworks (MOFs) are considered as promising candidates for supercapacitors because of high specific area and potential redox sites. However, their shuffled orientations and low conductivity nature lead to severely‐degraded performance. Designing an accessibly‐manipulated and efficient method to address those issues is of outmost significance for MOF application in supercapacitors. It is the common way that MOFs scarify themselves as templates or precursors to prepare target products. But to reversely think it, using target products to prepare MOF could be the way to unlock the bottleneck of MOFs' performance in supercapacitors. Herein, a novel strategy using Co(OH)₂ as both the template and precursor to fabricate vertically‐oriented MOF electrode is proposed. The electrode shows a double high specific capacitance of 1044 Fg^?1 and excellent rate capability compared to MOF in powder form. An asymmetric supercapacitor was also fabricated, which delivers a maximum energy density of 28.5 W h kg^?1 at a power density of 1500 W kg^?1, and the maximum of 24000 W kg^?1 can be obtained with a remaining energy density of 13.3 W h kg^?1. Therefore, the proposed strategy paves the way to unlock the inherent advantages of MOFs and also inspires for advanced MOF synthesis with optimum performance.     

纳米颗粒Gd@C_(82)(OH)_(22)抑制哺乳动物细胞外排转运的研究

目的 探讨纳米颗粒Gd@C_(82)(OH)_(22)体外对哺乳动物细胞外排转运的影响,研究该外排转运抑制作用与MRP1蛋白和ATP酶活性间的关系,为Gd@C_(82)(OH)_(22)应用于耐药肿瘤治疗提供初步实验依据.方法 通过Calcein-AM(C-AM)摄入法,以仓鼠肾细胞BHK-21、转染表达多药耐药相关蛋白MRP1的BHK-21/MRP1细胞以及肿瘤细胞PC-3为模型测定Gd@C_(82)(OH)_(22)对细胞外排转运的整体影响;用比色法测定Gd@C_(82)(OH)_(22)对MRP1蛋白截短体及BHK-21/MRP1质膜微囊的ATP酶活性的影响.结果 经Gd@C_(82)(OH)_(22)处理后,3种细胞的C-AM摄入量均上调,BHK-21与BHK-21/MRP1摄入量增加相似;用MRP1抑制剂MK571处理BHK-21/MRP1后,细胞C-AM摄入增长趋势不变;Gd@C_(82)(OH)_(22)对MRP1蛋白截短体及质膜微囊的ATP酶活性没有抑制作用.结论 表明Gd@C_(82)(OH)_(22)可抑制哺乳动物细胞的外排转运,其抑制作用并不是通过抑制MRP1蛋白或ATP酶活性来实现的.